



Acute Myeloid Leukemia in Adults

Guest Editor:

Dr. Theodoros Karantanos

Department of Oncology, Johns
Hopkins University, Baltimore,
MD 21218, USA

Deadline for manuscript
submissions:

closed (30 April 2025)

Message from the Guest Editor

Acute myeloid leukemia is the most common type of leukemia in adults and is caused by the acquisition of somatic mutations in hematopoietic stem and progenitor cells mediating their transformation to malignant cells that dominate the bone marrow. Despite the extensive investigation of the molecular biology of AML and the introduction of numerous novel agents and combinational approaches for the treatment of this disease, the outcomes of AML patients and particularly older individuals and those with antecedent myeloid neoplasms remain poor overall. A deeper and better understanding of the molecular pathways mediating the growth and resistance of AML blasts is required to introduce new therapies especially for resistant and relapsed forms of AML. This can be achieved by collaborative approaches in AML research and better comprehension of the resistant patterns to the current therapeutic approaches.

This Special Issue discusses the recent discoveries related to the biology of AML, the current therapeutic landscape and possible mechanisms of resistance to the current treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)